At the last check, PLx Pharma Inc. (PLXP) shares were trading at $19.50, an increase of 14.84 percent in after-hours trading. PLXP stock rose 1.68% on Monday to close at $16.98. On the day, 0.73 million shares of PLXP stock were traded, which was higher than the average daily volume of 0.46 million shares. In the last 12 months, shares of PLXP have risen 487.54%, and they have risen 36.60% in the last week.
Over the past three months, PLXP has seen its stock rise 61.56%, but over the past six months, it has tumbled 185.79%. In addition, PLXP is currently listed at $392.41 million on the market and its shares outstanding stand at 22.98 million. As part of its business strategy concerning expanding the availability of VAZALORE, PLXP stock rose.
How did PLXP make that move?
PLx is a specialty pharmaceutical company whose PLxGuard drug delivery platform has been clinically validated and is patent-protected, and which is dedicated to creating safer products and more effective therapies. The PLxGuard drug delivery platform allows PLXP to target pharmaceutical ingredients to specific regions of the gastrointestinal (GI) tract. Through the platform PLXP has developed, many drugs that are currently available or are in development could be better absorbed and increase the risk of stomach erosions and ulcers associated with certain drugs. PLXP’s leading products include VAZALORE 325 mg and VAZALORE 81 mg, referred to collectively as “VAZALORE”.
PLx announced that more than 8,000 Walgreens locations nationwide will begin to offer three stock-keeping units (SKUs) of VAZALORE ” a liquid-filled aspirin capsule that is first and only capsule approved by the Food and Drug Administration (FDA).
- The Walgreens chain of retail pharmacies is among the world’s leading brands.
- In order to reserve floor space at Walgreens for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count, placeholders have already been placed.
- PLXP has moved ahead with its commercial launch plans by partnering with Walgreens, which will carry all three SKUs of VAZALORE in over 8,000 of the company’s stores.
- Walmart’s health and wellbeing focus is aligned with PLXP’s aim of bringing VAZALORE to as many people as possible so they can benefit from PLXP’s unique aspirin therapy.
What PLXP has announced previously?
PLx (PLXP) last week announced that its VAZALORE products will be sold at more than 4,500 Walmart stores in the United States by mid-August. As a result, Walmart has already inserted placeholders on the shelves to alert customers about the arrival of PLXP’s VAZALORE. At the time, Walmart committed to stocking all three VAZALORE product SKUs in the next few weeks, using “Coming Soon” placeholder shelves.